Evidence map›Paper›PMID 32959085›Full record

Observational studyCardiovascular and interventional radiology2021

Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).

Thomas Helmberger, Rita Golfieri, Maciej Pech, Thomas Pfammatter, Dirk Arnold, Roberto Cianni, Geert Maleux, Graham Munneke, Olivier Pellerin, Bora Peynircioglu and 6 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cardiovascular and interventional radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02305459 (CIRSE Registry for SIR-Spheres Therapy), which is not on this map. Cited by 49 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02305459 completednot on this map

CIRSE Registry for SIR-Spheres Therapy

Typeobservational_patient_registrySponsorCardiovascular and Interventional Radiological Society of EuropeRan2014 to 2020Enrolled1,051ConditionsLiver CarcinomaArmsYttrium-90 loaded SIR-Spheres microspheres, QLQ-C30 with HCC module
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Trial
  7. Association of adverse events and quality of life in patients with unresectable hepatocellular carcinoma.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Trial
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Thomas HelmbergerDepartment of Radiology, Neuroradiology and Minimal-Invasive Therapy, Klinikum Bogenhausen, Englschalkinger Str. 77, 81925, Munich, Germany.
Rita GolfieriRadiology Unit, Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Hospital, University of Bologna, Via Bagni di Mario 15, 40136, Bologna, Italy.
Maciej PechDepartment of Radiology and Nuclear Medicine, University of Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany.
Thomas PfammatterInstitut für Diagnostische und Interventionelle Radiologie, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
Dirk ArnoldOncology and Hematology, Asklepios Tumorzentrum Hamburg, AK Altona, Paul-Ehrlich-Str. 1, 22763, Hamburg, Germany.
Roberto CianniDepartment of Interventional Radiology, S. Camillo Hospital, Circonvallazione Gianicolense, 85, 00149, Rome, Italy.
Geert MaleuxRadiology, Universitair Ziekenhuis Leuven, Herestraat 49, 3000, Leuven, Belgium.
Graham MunnekeInterventional Oncology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, NW1 2PG, London, UK.
Olivier PellerinInterventional Radiology Department, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015, Paris, France.
Bora PeynirciogluDepartment of Radiology, School of Medicine, Hacettepe University, Sihhiye Campus, 06100, Ankara, Turkey.
Bruno SangroLiver Unit, Clínica Universidad de Navarra, IDISNA and CIBEREHD, Avda. Pio XII 36, 31008, Pamplona, Spain.
Niklaus SchaeferService de médecine nucléaire et imagerie moléculaire, Inselspital Hospital Lausanne, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Niels de JongClinical Research Department, Cardiovascular and Interventional Radiological Society of Europe, Neutorgasse 9, 1010, Vienna, Austria. dejong@cirse.org.ORCID http://orcid.org/0000-0002-2377-2973
José Ignacio BilbaoInterventional Radiology, Clínica Universidad de Navarra, Avenida Pio XII, No 36, 31008, Pamplona, Spain.
On behalf of the CIRT Steering Committee
On behalf of the CIRT Principal Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT). MATERIALS AND

methodsPatients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected.

resultsTotally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4) for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE.

conclusionIn the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile. LEVEL OF EVIDENCE: Level 3.

trial registrationClinicalTrials.gov NCT02305459.

Indexed as

RegistriesCarcinoma, HepatocellularEmbolization, TherapeuticEuropeFemaleHumansIncidenceLiver NeoplasmsMaleMicrospheresMiddle AgedProspective StudiesRadiographyRetrospective StudiesYttrium RadioisotopesYttrium RadioisotopesHepatocellular carcinomaLiverMetastasisObservational studyRadioisotope brachytherapyRegistriesTherapeutic embolizationTrans-arterial radioembolizationYttrium-90

Identifiers

PMID32959085
PMCPMC7728645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.